Liver cancer ranks among the more painful solid-organ cancers, and the pain tends to worsen as the disease progresses. In an interview study of patients with hepatocellular carcinoma (the most common type of primary liver cancer), nine out of ten reported pain over the course of their treatment, and more than half rated its importance at 8 or higher on a 0-to-10 scale.1PubMed. Important and relevant symptoms including pain concerns in hepatocellular carcinoma (HCC): a patient interview study What makes liver cancer pain especially tricky is that the organ itself complicates the very drugs meant to treat that pain, creating a management puzzle that requires careful coordination across multiple treatment strategies.
Where Liver Cancer Pain Comes From
The liver itself has almost no pain-sensing nerve fibers in its inner tissue. You could poke the interior of a healthy liver and feel nothing. Pain arises instead from the thin membrane that wraps around the organ, known as the hepatic capsule. As a tumor grows, it stretches that capsule outward, and this stretching activates nerve endings that send pain signals. The larger the tumor burden, the greater the stretch and the more intense the pain tends to be. Pain can also come from the tumor pressing on surrounding structures, or from the release of inflammatory chemicals that make nearby nerves more sensitive.2PubMed Central. Hepatocellular cancer pain: impact and management challenges
The abdomen is the most commonly reported site. In one patient study, the upper abdomen was the primary location, followed by the lower back.1PubMed. Important and relevant symptoms including pain concerns in hepatocellular carcinoma (HCC): a patient interview study Back pain develops when a large tumor presses against the posterior abdominal wall or when cancer invades the spine. But one of the more puzzling locations is the right shoulder. When a liver tumor irritates the diaphragm, the phrenic nerve carries the signal up to the C3-C5 spinal levels, and the brain interprets it as shoulder pain. This referred pain can be the first symptom that leads to a cancer diagnosis, and it sometimes gets mistakenly treated as a musculoskeletal problem for weeks or months before the real cause is found.3PubMed Central. Liver Metastasis: A Rare and Sinister Cause of Shoulder Pain
Why Pain Management Is Harder With a Damaged Liver
Most liver cancers develop in livers that are already sick. Roughly 80 to 90 percent of hepatocellular carcinomas arise in the setting of cirrhosis from hepatitis, alcohol use, or metabolic disease. This complicates pain treatment in a fundamental way: the organ responsible for processing most painkillers is the same organ that is diseased. Drug metabolism becomes unpredictable, and medications that are perfectly safe for someone with a healthy liver can trigger dangerous side effects in someone with cirrhosis.4PubMed Central. The assessment and management of pain in cirrhosis
This creates a frustrating situation for patients. They may be told that the usual pain medicines are off limits or need to be used at much lower doses, leaving them feeling undermedicated. Pain in liver cancer patients is, by many accounts, undertreated, partly because clinicians are cautious about causing further liver damage and partly because the unpredictable drug metabolism makes dosing more art than science.
Acetaminophen, NSAIDs, and the Drug-Choice Problem
You might expect that acetaminophen (the active ingredient in Tylenol) would be the last thing a doctor prescribes for someone with liver disease, given its reputation for liver toxicity. But at reduced doses, it is actually considered the safest first-line painkiller for patients with cirrhosis. Reviews of the evidence consistently put the recommended ceiling at about 2 grams per day for cirrhotic patients who are not actively drinking alcohol, roughly half the standard maximum for healthy adults.5PubMed. The Safe Use of Analgesics in Patients with Cirrhosis: A Narrative Review 6PubMed Central. The Therapeutic Use of Analgesics in Patients With Liver Cirrhosis: A Literature Review and Evidence-Based Recommendations
Non-steroidal anti-inflammatory drugs like ibuprofen and naproxen, on the other hand, are generally off the table. In cirrhosis, NSAIDs can worsen kidney function, blunt the effect of diuretics used to control fluid buildup, and increase the risk of bleeding from the gut, including from varices (swollen blood vessels in the esophagus or stomach) caused by portal hypertension.7PubMed Central. Pain management in the cirrhotic patient: the clinical challenge One review notes a narrow exception: the selective COX-2 inhibitor celecoxib can be used for up to five days in patients with milder cirrhosis, at half the usual dose.5PubMed. The Safe Use of Analgesics in Patients with Cirrhosis: A Narrative Review But as a practical matter, most clinicians steer clear of the entire drug class in these patients.
Opioids in Liver Cancer
When acetaminophen alone is not enough, opioids become part of the conversation, and that conversation is complicated. The liver metabolizes most opioids through cytochrome P450 enzymes, and when those enzymes are impaired, the drugs linger in the body longer than expected. The practical result is a higher risk of sedation, constipation, and a particularly feared complication: hepatic encephalopathy, a buildup of toxins that causes confusion, personality changes, and in severe cases, coma.8PubMed Central. Opioid Drugs in Patients With Liver Disease: A Systematic Review
The standard approach is to start with a lower dose than you would in a patient with a healthy liver, extend the time between doses, and watch closely for signs of drug accumulation. Some opioid formulations come combined with naloxone, an opioid-blocking agent meant to counteract constipation. But in patients with liver impairment, portal hypertension or internal vascular changes can increase the amount of naloxone that reaches the bloodstream, which may partially block the opioid’s painkilling effect. This can happen even in patients without obvious cirrhosis, making the interaction easy to miss.9PubMed. Oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe, chronic cancer pain: Challenges in the context of hepatic impairment
Despite these risks, opioids remain essential for many liver cancer patients. The key is careful, individualized dosing and continuous reassessment rather than rigid protocols. When clinicians track pain scores, daily functioning, and bowel health at each visit, they can adjust more safely.10PubMed. Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma
Pain Caused by Liver Cancer Treatments
Liver cancer treatment itself can be a significant source of pain. One of the most common procedures for tumors that cannot be surgically removed is transarterial chemoembolization, or TACE, which delivers chemotherapy directly to the tumor while cutting off its blood supply. The treatment is effective, but up to 80 to 90 percent of patients develop what is called postembolization syndrome: a combination of fever, nausea, and abdominal pain that typically sets in within one to three days.11Surgery, Gastroenterology and Oncology. Determining Risk Factors for Post-Embolization Syndrome in Patients Undergoing TACE for Hepatic Malignancies The syndrome is self-limiting, meaning it resolves on its own, but the experience can be rough enough to make patients dread the next session.
There is an interesting and somewhat counterintuitive finding here: postembolization syndrome occurs more often in patients who achieve complete tumor remission than in those with only a partial response. In other words, the patients who benefit most from TACE tend to suffer the most from it in the short term. A meta-analysis found that giving dexamethasone (a steroid) before the procedure cut the rate of abdominal pain by about 40 percent and cut fever by more than half, making it one of the more effective preventive strategies available.12PubMed Central. Efficacy of prophylactic dexamethasone in reducing post-embolization syndrome following transcatheter arterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis
Radioembolization using yttrium-90 microspheres is another locoregional therapy that is generally better tolerated than TACE. While not free from side effects, the pain and nausea tend to be milder, and the fatigue that follows is usually the dominant complaint rather than acute abdominal pain.13PubMed Central. Recognizing and Managing Adverse Events in Y-90 Radioembolization
Radiation for Bone Metastases
When liver cancer spreads to bone, the resulting pain can be severe and localized, often dramatically affecting mobility and quality of life. External beam radiotherapy is one of the most reliable tools for this specific problem. In one large study, pain relief was achieved in over 99 percent of patients with bone metastases from hepatocellular carcinoma.14PubMed. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy Another study reported an overall pain response rate of about 81 percent, though the difference between higher and lower radiation doses was not significant for pain relief specifically.15PubMed Central. High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma
The distinction matters because higher doses may be better for local tumor control without necessarily providing more pain relief. For patients whose primary concern is pain rather than tumor shrinkage, a shorter, lower-dose course may be just as effective and less disruptive.16PubMed Central. Palliative external-beam radiotherapy for bone metastases from hepatocellular carcinoma
Celiac Plexus Procedures
For deep abdominal pain that does not respond well to medications, interventional pain specialists can target the celiac plexus, a network of nerves behind the stomach that carries pain signals from the upper abdomen. A celiac plexus block involves injecting local anesthetic (and sometimes a steroid) to temporarily silence these nerves, while neurolysis uses alcohol or phenol to damage them more permanently. Both are performed with image guidance and are minimally invasive.17PubMed Central. Celiac Plexus Block and Neurolysis in the Management of Chronic Upper Abdominal Pain
In a study of 51 terminal cancer patients who underwent celiac plexus neurolysis, pain scores dropped from an average of about 5.8 to 3.6 within a week, and scores improved in over 86 percent of patients. None experienced worsening pain. The most common side effect was temporary local pain at the injection site, lasting about 36 hours on average, along with some short-lived low blood pressure and diarrhea. Serious complications were not observed.18Journal of Hospice and Palliative Care. Celiac Plexus Neurolysis for the Treatment of Patients with Terminal Cancer at a Tertiary University Hospital in Korea A separate study using ultrasound-guided neurolysis found that about 80 percent of patients got immediate relief, though this faded over time, with roughly 57 percent still experiencing relief at two months and about 29 percent at three months. The median duration of benefit was close to three months.19PubMed. Contrast-enhanced ultrasound-guided celiac plexus neurolysis in patients with upper abdominal cancer pain: initial experience
The main value of these procedures may not be pain elimination but opioid reduction. By dampening the pain signal at its source, patients can lower their opioid doses, which in turn reduces the risk of encephalopathy, sedation, and constipation. For liver cancer patients in particular, any strategy that decreases opioid dependence carries outsized benefits.
Intrathecal Drug Delivery for Severe Pain
When pain is truly refractory, meaning it does not respond adequately to oral or intravenous medications and nerve block procedures, intrathecal drug delivery becomes an option. This involves placing a catheter in the spinal fluid space and delivering tiny doses of pain medication directly to the spinal cord, bypassing the liver entirely. Because the drug reaches pain receptors directly, the doses needed are a fraction of what would be required orally, and systemic side effects drop dramatically.
Intrathecal opioid therapy has shown particular promise for visceral pain like that caused by liver tumors and for somatic pain from bone metastases.20Pain Medicine. Intrathecal Therapy for Cancer-Related Pain In one study of advanced cancer patients fitted with intrathecal infusion ports, average pain scores fell from about 7.4 before treatment to roughly 2.0 a week afterward and stayed near that level a month later. Physical health scores improved alongside the pain reduction.21PubMed. Impact of intrathecal infusion port system on patients with advanced cancer pain and their caregivers The magnitude of that drop, from severe to mild, is striking and illustrates why the approach is considered when other routes have failed.
Acupuncture and Complementary Approaches
Research into acupuncture for liver cancer pain has grown in recent years, particularly in East Asian clinical settings where acupuncture is integrated into routine cancer care. A meta-analysis of 17 randomized controlled trials involving over 1,100 patients found that acupuncture provided meaningful pain relief when added to standard analgesic therapy, with the method used, the duration of treatment, and patient age all affecting how well it worked.22PubMed. Acupuncture treatment for liver cancer pain: A meta-analysis A broader network meta-analysis of 27 studies and over 2,200 patients compared different acupuncture-related modalities and found that acupuncture combined with moxibustion, when added to the standard stepwise painkiller approach, ranked highest for overall pain relief. Herbal acupoint application, which involves placing medicated patches on acupuncture points, ranked highest for reducing pain intensity scores and also had the fewest adverse events.23PubMed Central. Efficacy of Acupuncture Combined with the Three-Step Analgesic Protocol in Treating Pain in Liver Cancer Pain: A Bayesian Network Meta-Analysis
An important caveat: the evidence quality across these studies remains low, and many of the trials have small sample sizes and methodological limitations. The researchers behind these reviews consistently call for larger, more rigorous studies. Still, for patients looking for supplementary strategies, especially those who are already maxed out on what their compromised liver can handle in terms of medication, acupuncture appears to be low-risk and may offer meaningful additional relief. It is not a replacement for the stepwise analgesic approach but an addition to it.
The Role of Early Palliative Care
Palliative care for liver cancer is often misunderstood as something reserved for the final weeks of life. In reality, it can start at diagnosis and run alongside curative or life-extending treatments. For hepatocellular carcinoma specifically, palliative care addresses not just physical pain but the complex emotional and informational needs that shift at each stage of illness. Patients with liver cancer frequently carry the added burden of stigma associated with the underlying liver disease, whether from hepatitis, alcohol use, or metabolic conditions, and palliative specialists are trained to navigate those conversations.24PubMed Central. Palliative Care for People with Hepatocellular Carcinoma and Specific Benefits to Older Adults
In practical terms, a palliative care team can coordinate the competing demands of liver-safe pain management, treatment side effects, nutritional support, and advance care planning. For older adults, who make up a large share of liver cancer patients, the benefits are especially pronounced because they tend to have more comorbidities, process drugs less efficiently, and face more complex medication interactions. Having a team focused specifically on quality of life alongside the oncology team can prevent the common scenario where pain is addressed only in passing during tumor-focused visits.
When Shoulder or Back Pain Turns Out to Be Liver Cancer
One underappreciated aspect of liver cancer pain is how often it masquerades as something else. The referred shoulder pain discussed earlier is a classic example, but it is not the only one. Back pain from liver cancer pressing on posterior structures can mimic a herniated disc. Generalized abdominal discomfort may be attributed to indigestion. Because the liver can harbor sizable tumors before producing symptoms, the pain may appear suddenly when a growing mass finally stretches the capsule beyond a threshold or invades a nerve-rich area.
For someone already diagnosed with liver disease or cirrhosis, any new, unexplained pain warrants investigation rather than assumption. Hepatocellular carcinoma surveillance guidelines exist precisely because the cancer can grow silently, and pain is often a late sign. Clinicians sometimes describe a catch-22: by the time a patient with liver disease develops significant pain, the cancer may have advanced considerably, narrowing treatment options and making pain management both more urgent and more challenging. The takeaway for patients and their families is that persistent new pain in the setting of known liver disease should prompt early evaluation, not wait-and-see.